📣 VC round data is live. Check it out!

Kuros Biosciences Valuation Multiples

Discover Kuros Biosciences' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Xvivo Perfusion, SEEGENE, Dynavox Group, LifeTech Scientific and more.

Kuros Biosciences Overview

About Kuros Biosciences

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.


Founded

2016

HQ

Switzerland

Employees

122

Financials (LTM)

Revenue: $169M
EBITDA: $20M

EV

$921M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Kuros Biosciences Financials

Kuros Biosciences reported last 12-month revenue of $169M and EBITDA of $20M.

In the same LTM period, Kuros Biosciences generated $146M in gross profit, $20M in EBITDA, and $7M in net income.

Revenue (LTM)


Kuros Biosciences P&L

In the most recent fiscal year, Kuros Biosciences reported revenue of $186M and EBITDA of $16M.

Kuros Biosciences is profitable as of last fiscal year, with gross margin of 89%, EBITDA margin of 9%, and net margin of 2%.

See analyst estimates for Kuros Biosciences
LTMLast FY202320242025202620272028
Revenue$169M$186M$43M$96M$186M
Gross Profit$146M$165M$30M$79M$165M
Gross Margin86%89%71%82%89%
EBITDA$20M$16M($13M)($714K)$11M
EBITDA Margin12%9%(31%)(1%)6%
EBIT Margin7%6%(39%)(7%)6%
Net Profit$7M$3M($17M)($5M)$3M
Net Margin4%2%(41%)(5%)2%

Financial data powered by Morningstar, Inc.

Kuros Biosciences Stock Performance

Kuros Biosciences has current market cap of $944M, and enterprise value of $921M.

Market Cap Evolution


Kuros Biosciences' stock price is $23.94.

Kuros Biosciences share price decreased by 12.4% in the last 30 days, and by 31.0% in the last year.

Kuros Biosciences has an EPS (earnings per share) of $0.08.

See more trading valuation data for Kuros Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$921M$944M-3.0%-12.4%-16.0%-31.0%$0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Kuros Biosciences Valuation Multiples

Kuros Biosciences trades at 5.4x EV/Revenue multiple, and 46.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Kuros Biosciences

EV / Revenue (LTM)


Kuros Biosciences Financial Valuation Multiples

As of June 3, 2026, Kuros Biosciences has market cap of $944M and EV of $921M.

Kuros Biosciences has a P/E ratio of 142.1x.

LTMLast FY202320242025202620272028
EV/Revenue5.4x5.0x21.6x9.6x5.0x
EV/EBITDA46.4x57.6x(69.6x)n/m82.7x
EV/EBIT76.6x80.9x(54.9x)(145.0x)80.9x
EV/Gross Profit6.3x5.6x30.3x11.7x5.6x
P/E142.1xn/m(54.0x)(199.6x)n/m
EV/FCFn/mn/m(79.0x)n/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Kuros Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Kuros Biosciences Margins & Growth Rates

Kuros Biosciences grew revenue by 8% and EBITDA by 57% in the last fiscal year.

In the most recent fiscal year, Kuros Biosciences reported gross margin of 89%, EBITDA margin of 9%, and net margin of 2%.

See estimated margins and future growth rates for Kuros Biosciences

Kuros Biosciences Margins

Last FY202420252026202720282029
Gross Margin89%82%89%85%
EBITDA Margin9%(1%)6%13%
EBIT Margin6%(7%)6%8%
Net Margin2%(5%)2%6%
FCF Margin(2%)3%(2%)1%

Kuros Biosciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth8%125%93%8%
Gross Profit Growth4%159%109%4%
EBITDA Growth57%(95%)(1660%)125%
EBIT Growth43%(62%)(279%)43%
Net Profit Growth276%(73%)(169%)276%
FCF Growth(160%)(122%)(243%)(148%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Kuros Biosciences Operational KPIs

Kuros Biosciences' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.3M for the same period.

Kuros Biosciences' Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Kuros Biosciences' Rule of X is 33% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Kuros Biosciences
LTMLast FY202320242025202620272028
Rule of 4044%21%---
Bessemer Rule of X93%33%---
Revenue per Employee-$1.5M---
Opex per Employee-$1.3M---
S&M Expenses to Revenue57%49%51%48%49%
G&A Expenses to Revenue15%13%11%7%7%
R&D Expenses to Revenue8%7%17%9%7%
Opex to Revenue-82%111%89%82%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Kuros Biosciences Competitors

Kuros Biosciences competitors include Xvivo Perfusion, SEEGENE, Dynavox Group, LifeTech Scientific, QuidelOrtho, Anteris Technologies US, Artivion, ChemoMetec, MedicalSystem Technology and Barco.

Most Kuros Biosciences public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Xvivo Perfusion10.0x9.3x50.4x43.9x
SEEGENE1.9x1.9x7.4x7.7x
Dynavox Group3.7x3.6x16.2x15.1x
LifeTech Scientific3.7x-17.1x-
QuidelOrtho1.3x1.3x6.1x6.0x
Anteris Technologies US327.4x141.9x(7.0x)(6.3x)
Artivion2.7x2.6x13.3x12.9x
ChemoMetec12.2x11.9x23.3x21.7x

This data is available for Pro users. Sign up to see all Kuros Biosciences competitors and their valuation data.

Start Free Trial

Acquisitions by Kuros Biosciences

Kuros Biosciences has acquired 1 company to date.

Last acquisition by Kuros Biosciences was on December 19th 2016. Kuros Biosciences acquired Xpand Biotechnology for $35M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Kuros Biosciences

Xpand Biotechnology
Description
Xpand Biotechnology BV is a Dutch biotech firm in Bilthoven developing bone repair and regeneration products using proprietary surface science technology. It operates R&D, manufacturing, and clean room facilities for orthopedic applications. Products available via xpand-biotech.com.
HQ CountryNetherlands
HQ City
Utrecht
Deal Date19 Dec 2016
Valuation$35M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Kuros Biosciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Kuros Biosciences

When was Kuros Biosciences founded?Kuros Biosciences was founded in 2016.
Where is Kuros Biosciences headquartered?Kuros Biosciences is headquartered in Switzerland.
How many employees does Kuros Biosciences have?As of today, Kuros Biosciences has over 122 employees.
Is Kuros Biosciences publicly listed?Yes, Kuros Biosciences is a public company listed on SIX Swiss Exchange.
What is the stock symbol of Kuros Biosciences?Kuros Biosciences trades under KURN ticker.
When did Kuros Biosciences go public?Kuros Biosciences went public in 2002.
Who are competitors of Kuros Biosciences?Kuros Biosciences main competitors include Xvivo Perfusion, SEEGENE, Dynavox Group, LifeTech Scientific, QuidelOrtho, Anteris Technologies US, Artivion, ChemoMetec, MedicalSystem Technology, Barco.
What is the current market cap of Kuros Biosciences?Kuros Biosciences' current market cap is $944M.
What is the current revenue of Kuros Biosciences?Kuros Biosciences' last 12 months revenue is $169M.
What is the current revenue growth of Kuros Biosciences?Kuros Biosciences revenue growth (NTM/LTM) is 32%.
What is the current EV/Revenue multiple of Kuros Biosciences?Current revenue multiple of Kuros Biosciences is 5.4x.
What is the current EBITDA of Kuros Biosciences?Kuros Biosciences' last 12 months EBITDA is $20M.
What is Kuros Biosciences' EBITDA margin?Kuros Biosciences' last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of Kuros Biosciences?Current EBITDA multiple of Kuros Biosciences is 46.4x.
What is the current FCF of Kuros Biosciences?Kuros Biosciences' last 12 months FCF is ($938K).
What is Kuros Biosciences' FCF margin?Kuros Biosciences' last 12 months FCF margin is (1%).
What is the current EV/FCF multiple of Kuros Biosciences?Current FCF multiple of Kuros Biosciences is (981.9x).
How many companies Kuros Biosciences has acquired to date?As of June 2026, Kuros Biosciences has acquired 1 company.
What was the largest acquisition by Kuros Biosciences?$35M acquisition of Xpand Biotechnology on 19th December 2016 was the largest M&A Kuros Biosciences has done to date.
What companies Kuros Biosciences acquired?Kuros Biosciences acquired Xpand Biotechnology.
In how many companies Kuros Biosciences has invested to date?Kuros Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Kuros Biosciences

Lists including Kuros Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial